Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Santen’s Corporate Philosophy Framework
Santen’s Corporate Philosophy Framework
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Digital Transformation
Digital Transformation
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Development Process
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2023
IR News
2023 IR News
RSS
IR News
12.01.2023
Santen Announces Status of Share Buyback
11.17.2023
Santen Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension
11.07.2023
Santen Reports the 2nd Quarter Fiscal 2023 Consolidated Performance
11.01.2023
Santen Announces Status of Share Buyback
10.02.2023
Santen Announces Status of Share Buyback
09.20.2023
Revision of Full-Year Earnings Forecasts
09.13.2023
Santen Publishes its Annual Integrated Report “Santen Report 2023”
09.04.2023
Notice Regarding Implementation of an Early Retirement Program
09.01.2023
Santen Announces Status of Share Buyback
08.03.2023
Santen Reports the 1st Quarter Fiscal 2023 Consolidated Performance
08.01.2023
Santen Announces Status of Share Buyback
07.21.2023
Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration and Restricted Stock Unit Plans
07.19.2023
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
07.03.2023
Corporate Governance Report
07.03.2023
Santen Announces Status of Share Buyback
06.28.2023
Notice of Corporate Officer Changes
06.27.2023
Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration and Restricted Stock Unit Plans
06.01.2023
Santen Announces Status of Share Buyback
05.11.2023
Notice of Board of Director and Corporate Auditor Nominations
05.11.2023
Santen Announces Share Buyback
05.11.2023
Recording of Extraordinary Losses in Non-consolidated Financial Results
05.11.2023
Santen Reports Fiscal 2022 Consolidated Performance
04.27.2023
Revision of Full-Year Earnings Forecasts
04.13.2023
Santen Announces New Medium-Term Management Plan (FY2023-FY2025)
03.27.2023
Santen Files for Manufacturing and Marketing Approval for STN1011402 (Epinastine Hydrochloride) Ophthalmic Cream in Japan - Applied once daily to periocular area, new formulation for treatment of allergic conjunctivitis-
03.27.2023
Santen Announces Completion of Share Buyback and Number of Shares to be Canceled
03.22.2023
Santen Announces Cancellation of Treasury Shares
03.01.2023
Notice of Corporate Officer Change
03.01.2023
Santen Announces Status of Share Buyback
02.08.2023
Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure
02.07.2023
Revision of Full-Year Earnings Forecasts
02.07.2023
Santen Reports the 3rd Quarter Fiscal 2022 Consolidated Performance
02.01.2023
Santen Announces Status of Share Buyback
01.05.2023
Santen Announces Status of Share Buyback
